Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/12/24 16:14 | 11/11/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 28 | S.d | -23,240 | 108.58 | 0 | -214 | 1,759 | D | |||||||||||||||
10/8/24 16:19 | 10/7/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Mock James M | MA | O | CFO | 11 | S.d | -982 | 104.53 | 0 | -9 | 10 | D | |||||||||||||||
9/10/24 16:15 | 9/9/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Klinger Shannon Thyme | MA | O | GC | 15 | S.d | -1,442 | 124.27 | 0 | -12 | 18 | D | |||||||||||||||
8/2/24 19:00 | 7/31/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Afeyan Noubar | MA | D | 36 | S | -89,534 | 125.60 | 0 | -713 | 14,969 | D | ||||||||||||||||
2/16/24 16:10 | 2/16/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 1 | S | -2,342 | 88.88 | 0 | -26 | 0 | 21,075 | D | ||||||||||||||
12/7/23 16:21 | 12/6/23 | MRNA | Health | BioPrd | Biological Products, (No Diag | Garay Arpa | MA | O | Chief Co | 2 | S.d | -106 | 93.50 | 0 | -1 | 4 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |